BioVersys Shareholders Approve All Board Proposals at Annual General Meeting

BioVersys AG (SIX: BIOV), a clinical-stage biopharmaceutical company focused on developing novel antibacterial treatments for multi-drug resistant (MDR) infections, announced today that all proposals by its Board of Directors were approved by shareholders at the Annual General Meeting (AGM). The company, based in Basel, Switzerland, is advancing its lead candidate BV100 into a global Phase 3 trial for Acinetobacter baumannii infections, a serious threat in hospital settings.

At the AGM, shareholders voted in favor of all agenda items, including the approval of the 2025 Annual Report, financial statements, and auditor reports. They also re-elected Seng Chin Mah as Chairman and re-elected David Hunstad, Marc Gitzinger, Marina von Schonau, and Ulrik Schulze to the Board. Newly elected was Ms. Simona Skerjanec, who joins as a member of the Board of Directors. Additionally, shareholders approved the maximum aggregate compensation for the Board until the 2027 AGM and for the Executive Committee for the 2027 financial year.

Dr. Seng Chin Mah, Chairman of the Board, expressed gratitude to shareholders for their continued trust and support. ‘Having achieved First Patient First Visit for the global BV100 Phase 3 trial, we are completely focused on eventually bringing this therapeutic option to patients in dire need,’ he said. He also thanked Dr. William Jenkins for his contributions during his board tenure and welcomed Ms. Simona Skerjanec to the Board.

The approval of these proposals comes at a critical time for BioVersys as it progresses its pipeline. The company’s most advanced program, BV100, is in Phase 3 for nosocomial infections caused by Acinetobacter baumannii, a pathogen identified by the World Health Organization as a critical priority for new antibiotics. Another key program, alpibectir, is in Phase 2 for tuberculosis, developed in collaboration with GlaxoSmithKline (GSK) and a consortium from the University of Lille, France.

The AGM results underscore shareholder confidence in BioVersys’ strategy and execution, particularly as the company navigates the challenging landscape of antibiotic development. The antimicrobial resistance (AMR) crisis continues to grow, with limited new treatments in the pipeline. BioVersys’ focus on MDR bacteria addresses a high unmet medical need, and the advancement of BV100 into late-stage trials is a significant milestone.

The minutes and relevant documents from the AGM, including the Annual Report, are available on the company’s website at https://ir.bioversys.com/investor-relations/financials/financial-reports and https://ir.bioversys.com/investor-relations/governance-csr/annual-general-meeting.

BioVersys, with its two internal technology platforms—TRIC and Ansamycin Chemistry—aims to overcome resistance mechanisms, block virulence production, and address chronic inflammatory microbiome disorders. The company’s success in advancing its pipeline could have significant implications for public health, offering new hope in the fight against drug-resistant infections.

This news story relied on content distributed by NewMediaWire. Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is BioVersys Shareholders Approve All Board Proposals at Annual General Meeting.

The post BioVersys Shareholders Approve All Board Proposals at Annual General Meeting appeared first on citybuzz.